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Pathophysiology, evaluation, and 
Management of edema in Childhood 
Nephrotic Syndrome
Demetrius Ellis*
Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, 
Pittsburgh, PA, USA
Generalized edema is a major presenting clinical feature of children with nephrotic syn-
drome (NS) exemplified by such primary conditions as minimal change disease (MCD). 
In these children with classical NS and marked proteinuria and hypoalbuminemia, the 
ensuing tendency to hypovolemia triggers compensatory physiological mechanisms, 
which enhance renal sodium (Na+) and water retention; this is known as the “underfill 
hypothesis.” Edema can also occur in secondary forms of NS and several other glomer-
ulonephritides, in which the degree of proteinuria and hypoalbuminemia, are variable. 
In contrast to MCD, in these latter conditions, the predominant mechanism of edema 
formation is “primary” or “pathophysiological,” Na+ and water retention; this is known 
as the “overfill hypothesis.” A major clinical challenge in children with these disorders is 
to distinguish the predominant mechanism of edema formation, identify other potential 
contributing factors, and prevent the deleterious effects of diuretic regimens in those with 
unsuspected reduced effective circulatory volume (i.e., underfill). This article reviews the 
Starling forces that become altered in NS so as to tip the balance of fluid movement in 
favor of edema formation. An understanding of these pathomechanisms then serves to 
formulate a more rational approach to prevention, evaluation, and management of such 
edema.
Keywords: edema, nephrotic syndrome, children/pediatrics, pathophysiology, management
iNTRODUCTiON
Edema is an essential clinical feature of the diagnosis of nephrotic syndrome (NS) of various etiolo-
gies. It is defined as a palpable swelling resulting from an accumulation of fluid in the interstitial fluid 
compartment. Massive generalized edema (anasarca) is common, especially in children with primary 
minimal change disease (MCD) and serves as the main clinical justification for hospital admission for 
“diuretic management.” In such children, the selective loss of large amounts of albumin in the urine 
leads to hypoalbuminemia and decreased plasma oncotic pressure favoring fluid sequestration in the 
interstitial fluid compartment, and secondarily triggers renal Na+ and fluid retention so as to preserve 
intravascular volume and blood pressure, hence preventing an “underfill” state. In contrast to MCD, 
in NS associated with glomerulonephritis the magnitude of the proteinuria is variable and reduc-
tion in GFR is common. Hence, in disorders, such as focal and segmental glomerulosclerosis, acute 
post-streptococcal glomerulonephritis, Henoch Schoenlein nephritis, lupus nephritis, and several 
other glomerulonephritides, intravascular fluid volume is typically normal or expanded because of 
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inappropriately stimulated Na+ and fluid retention which together 
with decreased GFR results in an “overfill” state. The clinical dis-
tinction of these two predominant physiological states is critical to 
the proper management of edema in children with NS. However, 
the role of hypoalbuminemia has been questioned, and it is appar-
ent that other mechanisms such as water retention and vascular 
permeability factors, and activation of channels that promote Na+ 
reabsorption, may also play an important role in edema forma-
tion in diverse causes of NS. Thus, multiple mechanisms acting 
simultaneously may explain the clinical variability in response 
to measures aimed at removing excessive fluid among individual 
children with NS. This has led to inconsistent or improper clinical 
evaluation and management of this relatively common disorder.
While the precise mechanism(s) of edema formation may be 
controversial and turn-around time of several laboratory tests 
used to confirm the underlying mechanism(s) may not be suf-
ficiently rapid so as to influence acute management decisions, 
in most cases, there is adequate information to aid the clinical 
differentiation of the underlying basic mechanism of edema. This 
review discusses the pathophysiological alterations that favor 
edema formation in NS. This background then serves as the basis 
for developing selection criteria for hospital admission of children 
with NS who may benefit from edema fluid removal, establishing 
more standard guidelines for the clinical evaluation of nephrotic 
edema, and delineation of more uniform management guidelines 
aimed at providing effective management of the edema. Ultimately, 
the goal of therapy is to minimize the risk for hypovolemia, acute 
kidney injury (AKI), and other potentially serious complications 
ensuing from inappropriate diuretic regimens.
PATHOPHYSiOLOGY OF eDeMA 
FORMATiON iN NS
Compared to adolescents and adults, neonates and younger 
children have a greater proportion of total body and interstitial 
(IS) fluid volume, which can double or triple because of edema 
related to NS (1). Nephrotic edema is a transudate with low 
protein concentration (<3 g/dL) and a few or no cells. In contrast 
to other forms of edema, it is pitting, tends to be generalized and 
is more prominent in dependent body areas in which capillary 
hydraulic pressure (PCAP) is high (ankles and feet), or in tissues 
with low resistance or low interstitial hydraulic pressure (PIF) 
(eyelids, gastrointestinal tract/abdomen, and scrotum).
It is apparent that while total body water remains constant 
during health, the fluid within each compartment is not static; 
there is continuous movement between compartments. The pro-
cess of diffusion across cell membranes by far accounts for most 
fluid turnover (about 80,000 L/day in a 70 kg adult). By contrast, 
nephrotic edema represents net movement of water from the 
intravascular (IV) into the IS fluid compartment through the 
process of filtration across the capillary wall. Such filtration is 
dependent on the balance or net gradient, between the hydrostatic 
pressure and the oncotic pressure gradients across the capillary, 
as initially described by Starling in 1896 (2–4). Starling’s equation 
or “Law” was later modified as it became apparent that the net 
filtration is also determined by Lp, S, and s, as shown below:
Net filtration LpS hydraulic pressure oncotic pressure)= × −
=
(∆ ∆
LpS× − − −[( ) ( )]Pcap  Pif cap ifs pi pi
 
Lp is the unit permeability (known as porosity or “hydraulic 
conductivity”) of the capillary wall, which in the kidney refers to 
the glomerular capillary; S is the surface area available for fluid 
movement; Pcap and Pif are the capillary and interstitial fluid 
hydraulic pressures; πcap and πif are the capillary and interstitial 
fluid oncotic pressures; and s represents the reflection coefficient 
of proteins across capillary walls which ranges from 0 for vessels 
completely permeable to proteins and approaches a value of 1.0 
in protein-free ultrafiltrate. The interstitial fluid oncotic pressure 
is derived primarily from filtered plasma proteins and to a lesser 
degree from proteoglycans in the interstitium.
Because of unique anatomy, physiological properties, and 
Starling forces of glomerular capillaries, the kidney plays a central 
role in total body fluid and electrolyte homeostasis as depicted 
elsewhere (5). Of note, the mean net ultrafiltration filtration pres-
sure in glomerular capillaries is quite small and amounts to only 
6–8 mmHg. Because normal glomerular capillaries are essentially 
impermeable to protein (so oncotic pressure in the filtrate is 
zero), this is a true ultrafiltrate with a high reflection coefficient 
(s is about 1.0). Several forces are altered in NS so as to favor 
net fluid filtration both in glomerular and in peripheral capil-
laries. These include reduction in πcap, increased Lp, elevation 
in Pcap depending on the underlying etiology of NS, increased 
πif and lymphatic vessel obstruction which may interfere with 
removal of filtered fluid thereby enhancing edema formation. 
Children with MCD tend to have more marked proteinuria and 
lower πcap than adults, while those with acute post-streptococcal 
glomerulonephritis tend to have Na+ retention and rise in Pcap, 
favoring edema formation.
While mathematically and conceptually sound in providing 
a theoretical framework, direct measurement of Starling forces 
is complex and particularly challenging to assess in NS in which 
there are multiple alterations acting in concert to alter all com-
ponents of Starling’s equation to different degrees in any given 
individual. For example, Lp can differ based on histopathologi-
cal cause of NS, type and extent of elaboration of permeability 
factors that affect pore size and protein permeability, secretion 
of neuroendocrine hormones involved in preserving Pcap, and 
the concentration of plasma and interstitial albumin and other 
proteins that influence πcap and πif. Thus, in clinical practice, 
a glimpse of the basic operative mechanisms is often inferred 
by clinical assessment of hypovolemic symptoms or signs and 
by measurement of a limited number of blood and urinary con-
formational biochemical studies. Consequently, from a practical 
standpoint, two major mechanisms of edema formation are prev-
alent. First, in relation to edema associated with MCD or other 
non- inflammatory conditions resulting in massive proteinuria, 
an increase in transcapillary oncotic pressure gradient is the 
single most important driver of edema formation. This is because 
albumin which contributes 6 mmHg of oncotic pressure per g/
dL, or, 24 out of 26 mmHg of normal plasma oncotic pressure, is 
markedly reduced in such disorders. According to the underfill 
hypothesis reduction in plasma oncotic pressure promotes net 
FiGURe 1 | Pathophysiology of edema formation in NS. In disorders with massive proteinuria and marked hypoalbuminemia but minimal or absent renal 
inflammatory infiltrate, as in most children with minimal-change disease (MCD), the reduction in capillary colloid oncotic pressure (πcap) favors net fluid exit from the 
vascular to the interstitial fluid compartment thereby reducing effective circulatory blood volume, denoted as “underfill.” This then triggers secondary, or 
compensatory, Na+ retention and hemodynamic alterations aimed at achieving blood pressure homeostasis. By contrast, various glomerulonephritides and 
inflammatory renal disorders, such as acute post-streptococcal glomerulonephritis, may be associated with variable degrees of proteinuria and with pathologic 
release of mediators, which promote primary renal Na+ and water retention, as well as vasoconstrictive hormones that are released despite an intact or even 
expanded intravascular volume. These factors together with reduction in glomerular ultrafiltration coefficient (Kf, or LpS in the Starling equation), lead to reduced 
glomerular filtration rate (GFR) and combine to further limit Na+ excretion, resulting in an “overfill” state and rise in capillary hydraulic pressure (Pcap). In turn, this 
causes net fluid accumulation in the interstitial fluid compartment. Note that nephrotic urine may be a common pathway for primary Na+ retention in both undefill and 
overfill disorders (refer to text and Tables 1–3 for the mediators sub-serving each of these main mechanisms of edema formation).
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movement of fluid out of the intravascular compartment, leading 
to volume depletion, or underfilling (6–12). This then causes 
appropriate or compensatory physiological activation of several 
mechanisms ultimately resulting in secondary Na+ and fluid reten-
tion aimed at restoring intravascular volume and blood pressure. 
This is the most prevalent mechanism in edematous children 
presenting with NS. This is in contrast to the second mechanism 
of nephrotic edema, or overfill hypothesis, exemplified by acute 
post-streptococcal glomerulonephritis and other inflammatory 
proteinuric disorders in which the pathophysiological process 
activates several mediators sub-serving primary Na+ retention, 
resulting in intravascular volume expansion, increased capillary 
hydraulic pressure and edema. A schema depicting the two major 
mechanisms of nephrotic edema is presented in Figure 1.
CONTROveRSY OF MeCHANiSMS OF 
NePHROTiC eDeMA
Primary vs. Secondary Na+ Retention
While previous schemes of nephrotic edema depicted Na+ reten-
tion through distinct secondary (in underfill) and primary (in 
overfill) mechanisms, there is now compelling evidence that 
primary Na+ retention may occur by a mechanism common to 
all individuals with “nephrotic urine,” independent of underlying 
histology or blood volume status [see below, Ref. (13)]. Several 
studies implicate loss of plasmin and other serine proteases in 
the urine in the up-regulation of the epithelial sodium channel 
(ENaC) causing Na+ and fluid retention (see below). This is also 
highlighted in Figure 1.
Blood volume Status
Based on clinical observations and theoretical grounds, the long 
held prevailing opinion has been that children and adults present-
ing with NS edema, are in a state of intravascular volume deple-
tion. Although a few studies support the presence of hypovolemia 
in adults with MCD compared to other histological forms of NS 
(14), and in some but not all children with MCD (15, 16), other 
investigations indicate that most adults and some children with 
NS of any cause have an adequate or expanded effective blood 
volume and do not exhibit orthostatic hypotension or other 
hypovolemic symptoms and signs (16–18).
To gain greater insight into the pathophysiology of edema in 
children with NS, Vande Walle et al. (19) studied children in early 
relapse of NS and found that they grouped into three presenta-
tions: (a) incipient proteinuria without edema, Na+ retention, and 
slightly elevated circulating aldosterone, increased renal plasma 
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flow, and normal norepinephrine (NE) levels; (b) symptoms 
of hypovolemia, edema, Na+ retention, elevated plasma renin, 
aldosterone and NE levels, low atrial natriuretic peptide, and 
reduced GFR; and (c) edema, no hypovolemia, no active Na+ 
retention, normal plasma hormones, and normal GFR.
These data are very important because they indicate that there 
is both clinical and biochemical heterogeneity in children with NS. 
Distinguishing these fundamental mechanisms aids, the clinical 
prediction of safety and benefit of diuretic therapy: diuretics are 
well tolerated in children with primary renal Na+ retention but, 
if underfilling is the predominant mechanism, diuretic use can 
exacerbate hypovolemia and tissue hypoperfusion.
Role of Hypoalbuminemia in Nephrotic 
edema
Figure  1 highlights the role of hypoalbuminemia in children 
with nephrotic edema. However, with the exception of marked 
hypoalbuminemia (<2.0  g/dL) and plasma oncotic pressures 
below 8–10 mmHg, several clinical and experimental observa-
tions call into question the central role of hypoalbuminemia in 
the pathogenesis of nephrotic edema (8). For example, studies in 
analbuminemic rats show no significant change in transcapillary 
oncotic pressure gradient or tendency to edema compared to 
controls (20). Also, 81% of individuals with congenital analbu-
minemia (dysfunction of the albumin gene resulting in marked 
hypoalbuminemia) have little or no edema (21). It appears that 
in this disorder, πcap is partially compensated over time by other 
plasma proteins and may explain the parallel decrease in πif.
Other observations in experimental animals as well as in 
humans undergoing repeated plasmapheresis to intentionally 
produce modest reductions in serum albumin concentrations 
show that the transcapillary oncotic gradient is preserved; only 
with greater degree or more rapid achievement of hypoproteine-
mia does blood volume fall and edema develops (22, 23). This 
is because as plasma oncotic pressure falls, a parallel reduction 
in tissue oncotic pressure also occurs. Moreover, administration 
of albumin concentrates does not appreciably mobilize edema 
fluid in many nephrotic subjects, although Na+ excretion can 
increase transiently in some (24–26). Finally, patients with MCD 
who are treated with corticosteroids often undergo a diuresis and 
natriuresis well before the serum albumin concentration starts to 
rise; this finding suggests that correction of the hypoalbumine-
mia might not be essential in steroid-induced natriuresis (27). 
However, several of the experimental conditions investigating the 
role of albumin per se in the pathomechanism of nephrotic edema 
may not be appropriate models for this condition in humans in 
whom vascular permeability factors and cytokines may, in fact, 
play an important role in preventing the counterbalance of 
oncotic pressure gradient evident in congenital analbuminemia 
or in experimental plasmapheresis.
Despite the controversy surrounding the “central role” of 
hypoalbuminemia in the development of edema in NS, nearly all 
children with NS and edema have hypoalbuminemia and in the 
author’s opinion this controversy has little baring on the clinical 
evaluation and management of edema.
Factors That Protect Against edema 
Formation in NS
Because normally there is a small net pressure gradient favoring 
net filtration across capillaries, it might be expected that only a 
minor change in these hemodynamic forces would lead to edema. 
However, experimental and clinical observations indicate that 
there must be at least a 15 mmHg increase in the net pressure gra-
dient favoring filtration before edema can be detected. With lesser 
reduction of this gradient, edema is unlikely to occur because of 
three compensatory factors (27, 28). First, experimental evidence 
indicates that there is increased lymphatic flow which, by bulk 
flow, will remove albumin as well, and help remove some of the 
excess filtrate (29, 30). Second, fluid entry into the interstitium 
will eventually raise the interstitial hydraulic pressure, thereby 
oppose filtration and interstitial fluid accumulation (28). Third, 
fluid accumulation in the interstitium simultaneously reduces 
interstitial oncotic pressure in subcutaneous tissue which in 
humans it is normally 12–15 mmHg (7). Thus, a gradual fall in 
plasma oncotic pressure in NS is associated with a parallel decline 
in interstitial oncotic pressure and rise in interstitial hydraulic 
pressure (7, 27), which minimizes the change in the transcapillary 
pressure gradients favoring net fluid movement out of the vascu-
lar space and results in relative preservation of plasma volume.
As a result of these compensatory physiological responses, 
there is usually little change in the transcapillary oncotic pres-
sure gradient in children with NS, and therefore little tendency to 
plasma volume depletion, unless the hypoalbuminemia is severe. 
Similarly, as long as children with NS are not overdiuresed, 
plasma volume is typically preserved during diuretic therapy for 
edema removal.
vOLUMe ReGULATORY HORMONeS 
SUB-SeRviNG UNDeRFiLL AND 
OveRFiLL MeCHANiSMS OF eDeMA 
FORMATiON iN NS
In children who are hypovolemic or “underfilled,” there is 
interplay of several volume regulatory hormones and nephron 
channels listed in Table 1, which tend to attenuate the effect 
of vascular underfilling mainly through modulation of renal 
Na+ and fluid retention. Activation of the RAAS is an impor-
tant mechanism in the majority of children presenting with 
nephrotic edema. It is notable that several of the hormones 
shown in Table 1, including AT II and anti-diuretic hormone 
(ADH), have dual Na+ or water retaining, and vasoconstriction 
properties, and are therefore very suitable in preserving sys-
temic blood pressure in children with NS and reduced circula-
tory volume. Similarly, NE release in response to stimulation 
of low pressure cardiopulmonary receptors mediates neuronal 
control of renal tubular Na+ reabsorption (31). Edema may 
thus be viewed as a byproduct of these adaptive processes.
In addition, there may be several relatively unique pathologi-
cal perturbations that promote edema formation in NS. Thus, 
children with acute post-streptococcal glomerulonephritis 
manifesting edema and hypertension often have increased 
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circulating ANP and reduced ADH, plasma renin activity, aldos-
terone, and NE concentrations. Experimental models of unilat-
eral NS or glomerulonephritis show increased Na+ reabsorption 
in the collecting tubules (26, 32), which is also the site of action 
of ANP and the related renal hormone urodilatin. Urodilatin 
is an ANP analog or isoform secreted by distal convoluted 
tubule (DCT) and collecting duct (CD) epithelium and exerts 
a paracrine function similar to ANP in promoting natriuresis 
and diuresis. In both experimental and human NS, a state of 
relative resistance to ANP and urodilatin has been observed (6, 
33–35). This defect is due at least in part to urinary plasmin loss 
in individuals with NS which then stimulates phosphodiesterase 
activity, leading to more rapid degradation of the second mes-
senger of ANP, cyclic guanosine monophosphate (cGMP), in 
the collecting tubules. Infusion of a phosphodiesterase inhibitor 
largely reverses this defect and restores the natriuretic response 
to volume expansion (33, 35).
Also, in many individuals with inflammatory forms of glo-
merulonephritis and NS there is activation of several tubular 
channels and transporters that promote Na+ reabsorption and 
edema formation. These include:
 1. Increased activity of the Na+-hydrogen exchanger (NHE3) 
that mediates a large portion of proximal Na+ reabsorption 
(36, 37). However, as demonstrated in experimental unilateral 
NS, overall Na+ retention is influenced to a larger degree by 
mechanisms that promote Na+ reabsorption in the distal 
tubule (26).
 2. Inactive plasminogen present in nephrotic urine is converted 
to active plasmin by the action of urokinase-type plasmi-
nogen activator. Cleavage and activation of γ subunit of the 
ENaC is then stimulated by the serine proteinase plasmin 
found in nephrotic urine, which may contribute to Na+ reten-
tion in the cortical collecting tubule (13, 38–41). This effect 
may be reversed by amiloride. This provides a common and 
potentially important mechanism by which filtered proteins 
cause primary Na+ retention regardless of the underlying 
histological form of NS or the child’s blood volume status. 
It also explains the clinical observation that spontaneous 
diuresis and edema improvement can occur in NS prior to 
a decrease in urinary protein excretion, despite ongoing 
hypoalbuminemia.
 3. Increased activity of the Na-K-ATPase pump in the cortical 
collecting tubule but not in other nephron segments (42). 
This transporter provides the energy for active Na+ transport 
by pumping reabsorbed Na+ out of the cell and aiding it is 
uptake into the peritubular capillary. However, it is not clear 
if this represents a primary defect or if it is simply a secondary 
marker for increased Na+ transport at this site.
Clinical evaluation of the Predominant 
Mechanism of edema formation in NS
Timely clinical assessment of hemodynamic aspects, including 
circulatory volume, is the key to determining management 
approaches to reduce edema in children with NS. This will 
help avoid exacerbation of the most common complication 
encountered in hospitalized children with NS and “underfill,” 
AKI (43), or hypertensive and pulmonary complications in those 
with “overfill.” Tables 2 and 3 summarize the typical clinical and 
laboratory features, which serve to distinguish children with NS 
with underfill or overfill physiology.
It should be noted that because Na+ retention occurs both in 
underfill and overfill states (Figure 1), it is not possible to use 
the FENa+ to clinically differentiate primary from secondary Na+ 
retention in NS. Also, measurement of several hormonal markers 
shown in Tables  2 and 3 are not readily measured in hospital 
laboratories and may not be clinically useful in confirming the 
underlying operative mechanism or influence point-of-care deci-
sions. However, an increase in RAAS and circulating aldosterone 
effect can be inferred on the basis of more readily measured values 
such as an increased transtubular potassium gradient (TTKG) 
index or, UK+/UK+ + UNa+, which is observed in hypovolemic 
children and not when blood volume is preserved. Similarly, a 
TTKG index below 60% along with FENa+ above 0.5%, and normal 
or suppressed plasma aldosterone concentrations, highly impli-
cate a primary Na+ retention mechanism leading to increased 
intravascular volume (i.e., overfill) (10, 19). This also suggests 
a primary role of aldosterone in the intrinsic activation of 
Na+/K+ ATPase in the cortical CD. Such children may benefit from 
diuretic use. By contrast, diuretic use in children with NS and 
secondary Na+ retention triggered by hypovolemia or circulatory 
TABLe 1 | Contribution of volume and blood pressure regulatory 
hormones and channels which mediate or participate in renal Na+ and 
edema formation in NS.
Hormones and channels Function
RAAS activation Direct stimulation of active Na+ 
reabsorption in the PCT by AT II; 
aldosterone-mediated Na+ retention
Non-osmotic ADH/vasopressin 
release
Water retention in CD, vasoconstriction
Norepinephrine (NE) release α-Adrenergic stimulation of renal tubular 
Na+ reabsorption; vasoconstriction
Atrial natriuretic peptide (ANP) 
release
Promotes natriuresis and diuresis in DCT 
and CD, but tubular epithelium is resistant 
to these effects in NS
Urodilatin activation Promotes natriuresis and diuresis in DCT 
and CD, but tubular epithelium is resistant 
to these effects in NS
Phosphodiesterase activation Promotes degradation of ANP and 
urodilatin
Sodium-hydrogen exchanger 3 
(NHE3) activation
Mediates Na+ reabsorption in PCT
Epithelial sodium channel (ENaC) 
activation by plasmin loss in 
nephrotic urine
Stimulates Na+ reabsorption in the DCT 
and CD
Sodium potassium ATPase  
(Na+/K+ ATPase) activation
Provides energy for pumps involved 
in active Na+ transport and facilitates 
peritubular uptake of Na+ by exporting Na+ 
out of cells in the anti-lumenal side of CCT
RAAS, renin angiotensin aldosterone system; AT II, angiotensin II; Na+/K+ ATPase, 
sodium potassium adenosine tri-phosphatase; DCT, distal convoluted tubule; CD, 
collecting duct; PCT, proximal convoluted tubule; CCT, cortical collecting tubule.
TABLe 4 | General aspects of management of edema in children with NS.
Avoid NSAiD use
Avoid placement of deep lines to prevent thromboembolic events
Reduce dietary salt
No fluid restriction unless brisk diuresis is achieved
Insure adequate nutrition
Monitor urine output, renal function, electrolytes, serum albumin, body weight, 
and vital signs
Elevate extremities or use compression stockings when ambulating; water 
immersion is helpful but impractical
Avoid ACE inhibitors as remission can occur in many children with 
corticosteroid monotherapy
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insufficiency may have serious deleterious consequences (see 
below).
MANAGeMeNT OF NePHROTiC eDeMA
Before reviewing the management of edema in children with NS 
it is worth noting the change in the incidence of known clinical 
complications of NS that may relate to edema or its improper 
medical management. In a recent study involving hospital 
discharges of 4,701 children admitted with NS, Rheault et  al. 
found that the frequency of infectious and thromboembolic 
complications has not changed much over the past 10  years; 
however, the incidence of AKI had increased from 3.3 to 8.5% 
(158%) over the period of 2001 and 2009 (43). The increasing 
use of nephrotoxic medications such as calcineurin inhibitors and 
angiotensin converting enzyme/angiotensin receptor blockers to 
co-manage steroid dependent and steroid resistant NS may be 
partly responsible for this trend. However, aggressive diuresis in 
children not recognized as having intravascular volume deple-
tion (underfilling) may enable progression from incipient AKI 
to established AKI. Furthermore, prevention of AKI is of great 
importance because it may be a precursor to future development 
of chronic renal injury and hypertension. Inappropriate diuresis 
may also promote a thrombotic tendency in this disorder (44–47). 
Consequently, children with “underfill” physiology may benefit 
first by circulatory volume expansion using salt-poor albumin 
infusions, and delayed start of diuretics until after restoration of 
tissue perfusion is achieved.
NON-PHARMACOLOGiCAL MeASUReS
Apart from managing the underlying condition leading to NS 
according to established guidelines (48–51), Table 4 summarizes 
other basic aspects of care. Because Na+ and fluid retention is a 
fundamental feature of all causes of NS and because treatment 
regimens that include corticosteroids tend to enhance this effect, 
all children presenting with edema are counseled on dietary Na+ 
restriction (35 mg Na+/kg/day, or approximately1.5 mEq/kg/day) 
and are monitored for clinical signs of hypovolemia (52). Fluid 
restriction is usually self-limited in children who adhere well to 
Na+ restriction, and it is not recommended in children managed 
in the outpatient setting.
Attention to nutrition is very important particularly in condi-
tions associated with massive proteinuria, such as Finnish type 
NS. Given the T1/2 of albumin of 21 days, when provided with 
adequate calories and amino acids, the liver can produce 200 mg 
albumin/kg/day to replace albumin catabolism or urinary loss. 
This normal synthetic function can double when the oncotic 
pressure in hepatic sinusoids falls as in the setting of NS. However, 
many children with NS are “picky eaters” and may have intestinal 
edema and abdominal pain, resulting in poor appetite as well as 
protein-losing enteropathy that may further compromise nutri-
tion. In addition, the degree of proteinuria may be underestimated 
because of the large influence of the proximal tubule in albumin 
catabolism in NS. Thus, recycled amino acids are not used to 
replace albumin exclusively. Provision of supplemental calories, 
egg white protein, and nutritional supplements, such as Boost or 
Pediassure, may be helpful if clinically indicated.
TABLe 2 | Mechanism of edema formation in nephrotic syndrome: 
“underfilling.”
Clinical characteristics
Neuromuscular weakness, pallor, cool extremities, tachycardia, and other signs 
and symptoms of orthostatic hypotension, abdominal pain secondary to gut 
edema, abdominal compartment syndrome, or thrombosis of vena cave or 
renal veins
Laboratory findings
Reduced urine volume
FENa+ < 0.2%
UK+/UK+ + Na+ > 60% (increased TTKG index)
Reduced urinary Na+ and high potassium concentration
Very low serum albumin (≤2 g/dL)
Low serum creatinine level
GFR > 75 mL/min/1.73 m2
Hemoconcentration
High circulating PRA, aldosterone, vasopressin, and norepinephrine
Low ANP concentration
FENa+, fractional excretion of sodium; UK+ and UNa+, urinary potassium and sodium 
concentrations; TTKG, transtubular potassium gradient; GFR, glomerular filtration rate; 
PRA, plasma renin activity; ANP, atrial natriuretic peptide.
TABLe 3 | Mechanism of edema formation in nephrotic syndrome: 
“overfilling.”
Clinical findings
Normal or elevated BP without tachycardia or orthostatic symptoms, and no 
signs to indicate distal extremity hypoperfusion
Laboratory findings
FENa+ > 0.5% while on no salt restricted diet
UK+/UK+ + UNa+ < 60% (decreased TTKG index)
Hematuria and cellular casts
Serum albumin >2 g/dL
Elevated serum creatinine and BUN
GFR < 50 mL/min/1.73 m2
Decreased vasopressin
Low circulating PRA and norepinephrine
Low or normal plasma aldosterone
High ANP
FENa+, fractional excretion of sodium; UK+ and UNa+, urinary potassium and sodium 
concentrations; TTKG, transtubular potassium gradient; GFR, glomerular filtration rate; 
PRA, plasma renin activity; ANP, atrial natriuretic peptide.
TABLe 6 | Diuretics used to manage edema in children.
Diuretic class, name, mechanism, and site 
of action
Bioavailability %  
PO/iv ratio
Onset of 
action (min)
PO/iv
Duration of 
action (h)
Dosing
Loop diuretics
Furosemide 60 1.5 40/5 6 Neonates: p.o. 1–4 mg/kg/dose, 1–2×/day iv/im 
1–2 mg/kg/dose q 12–24 h
Bumetanide 85 1 40/5 4 Children: p.o./iv/im 1–2 mg/kg/dose q 6–12 h
Torsemide, ethacrynic acid <6 months: p.o./iv/im 0.05–0.05 mg q 24 h
Inhibit the Na+/K+/2Cl− cotransport system in 
the thick ascending limb of Henle’s loop (ALH)
>6 months: p.o./iv/im 0.015 mg/kg q 24 h; 
max. 0.1 mg/kg/dose
Thiazide diuretics
Chlorothiazide 11–20 120 24 <6 months: p.o. 20–40 mg/kg/day divided bid iv 
2–8 mg/kg/day divided bid
Hydrochlorothiazide 60–75 120 12–24 >6 months: p.o. 20 mg/kg/day divided bid iv 4 mg/
kg/day
Inhibit NaCl cotransport in the early distal 
convoluted tubule (DCT)
<6 months: p.o. 2–3.3 mg/kg/dose divided bid
>6 months: p.o. 2 mg/kg/day divided bid
Thiazide-like
Metolazone 40–60 60 24 Children: 0.2–0.4 mg/kg/day divided q 12–24 h
Similar to thiazides but also proximal tubular 
inhibition of sodium uptake
TABLe 5 | Albumin infusion in the management of edema in NS.
Dosing of salt-poor albumin (25% SPA, or, 25 g/100 mL)
0.5 g/kg infused over 1-h, 2–3 times daily. Slower infusion rates may enhance 
equilibration of albumin between the intravascular and interstitial fluid 
compartments, thereby undermining fluid mobilization and removal. Larger 
dosages may be more effective but may cause acute volume expansion and 
pulmonary congestion
indications
Tense ascites with abdominal compartment syndrome limiting diaphragmatic 
excursion, lymphatic flow, and venous return
Severe pleural effusions compromising breathing
Oliguria with incipient acute kidney injury (AKI)
Marked eyelid edema compromising vision
Severe scrotal or labial edema, risking skin breakdown
Precautions
Expensive
Low supply
Obtained from multiple blood donors risking viral transmission, tissue 
allosensitization, etc.
Pulmonary edema
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Once a brisk diuresis is achieved, fluid intake may be limited to 
2/3 of maintenance, or 1/2 or less of urine output, so as to produce 
the intended negative Na+ and fluid balance. Close monitoring of 
vital signs, fluid input and output, and of electrolytes is required 
in order to assure safety. Diuretic therapy should be temporar-
ily discontinued if there is an unexplained decrease in urine 
output, elevation in serum creatinine or clinical manifestations 
of hypovolemia (e.g., weakness, orthostatic hypotension, and/or 
cool extremities) (52, 53).
PHARMACOLOGiCAL MANAGeMeNT OF 
NePHROTiC eDeMA
Albumin infusion
In hospitalized children with nephrotic edema, excessive fluid can 
usually be removed, relatively safely, without exacerbating volume 
depletion (refer to Table 5). This is often accomplished through 
the combined administration of salt-poor, or, 25% albumin (SPA) 
to facilitate reabsorption of IS fluid, thereby supporting plasma 
volume and diuretics to enhance fluid removal. The more avail-
able 5% albumin solution can increase blood volume but does 
not raise oncotic pressure, while it delivers fivefold higher Na+ 
for each gram of albumin infused. By expanding plasma volume, 
albumin infusion suppresses vasopressin release induced by 
hypovolemia, thereby increasing water diuresis and improve-
ment in hyponatremia. Albumin infusion is associated with 
more profound diuresis, at least in a subpopulation of pediatric 
patients with NS (54–57), particularly those with reduced effec-
tive arterial blood volume. For example, in one series of children 
with nephrotic edema and fractional excretion of Na+ (FENa+) of 
<0.2% suggesting reduced effective arterial blood volume were 
treated with diuretics plus albumin infusion (52). Their diuresis 
rivaled that obtained by diuretic monotherapy in children with 
FENa+ > 0.5% suggesting circulatory volume sufficiency or expan-
sion (58).
Table 5 lists specific indications for albumin infusion recom-
mended by the author. Caretakers should also carefully weigh 
the precautions or potential drawbacks to such therapy, and 
consider avoiding pharmacotherapy for edema particularly if 
prompt remission of NS is anticipated. Notably, cosmetic effects 
related to edema are not an indication for diuresis in children 
with NS.
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Non-Protein Colloid Alternatives
The clinical utility of non-albumin colloids, such as (hyperon-
cotic 12% dextran solution given at 1.2–1.8  g/kg body weight 
daily as a single dose or on 3–5 consecutive days), was previously 
investigated in children with nephrotic edema (59). The precise 
mechanism of action has not been clarified. However, despite 
being effective in achieving a brisk diuresis at a lower cost than 
albumin, dextran use has not gained clinical favor because of 
safety concerns including increased blood pressure, headache, 
gastrointestinal discomfort, pain upon tissue infiltration, and 
bleeding diathesis with epistaxis. The clinical response to other 
non-protein colloid alternatives such as gelatin and hydroxy-
ethyl starch to induce diuresis in nephrotic edema has not been 
investigated.
Angiotensin inhibition
Nearly, all children with chronic proteinuric disorders receive 
an ACE inhibitor or an angiotensin II receptor blocker as 
adjunctive synergistic drugs aimed at averting progressive 
renal injury caused by the underlying renal disorder. Such 
agents also exert a significant anti-proteinuric action and rise 
in serum albumin concentration which enhances the response 
to diuretics. However, the author recommends not using such 
agents in children with marked proteinuria because they tend to 
exaggerate hyponatremia and increase the risk of AKI because 
of lowering of systemic and intra-glomerular pressure. Although 
these agents serve as anti-proteinuric agents regardless of the 
underlying etiology of chronic proteinuria they are of little 
benefit in the acute management edema or if prompt remission 
of proteinuria is anticipated after staring steroids, as in the case 
of childhood MCD.
DiUReTiC MANAGeMeNT OF NePHROTiC 
eDeMA
Recognizing that in the majority of children nephrotic edema 
is the result of appropriate compensatory physiological mecha-
nisms aimed at restoring diminished circulatory volume and 
tissue perfusion, use of diuretics to remove edema fluid should be 
undertaken with great caution so as not to interfere with adaptive 
responses (refer to Table 6).
With the possible exception of children with inflammatory 
glomerulonephritis, nephrotic edema and coexisting hyperten-
sion or clear evidence of “overfilling,” the author rarely recom-
mends diuretic use in the outpatient setting. This is because of the 
potentially catastrophic risks of diuretic use in NS, such as throm-
bosis and thromboembolism, AKI, and electrolyte imbalance. By 
contrast, concurrent use of diuretics and salt-poor albumin or 
diuretic monotherapy is often utilized to manage edema in the 
inpatient setting.
Many children with NS respond well to loop diuretics, although 
there is generally lesser natriuresis than when such diuretics are 
utilized to manage edema associated with other medical disorders 
(60, 61). Experimental studies in drug-induced NS suggest that 
the loop of Henle may be relatively resistant to loop diuretics (62). 
Several factors are thought to play an important role in inducing 
this relative diuretic resistance:
 1. Because most diuretics are highly protein-bound, they 
tend to become trapped within the vascular compartment, 
thereby maximizing their rate of delivery to the kidney. In 
NS however, the degree of protein binding is reduced due to 
hypoalbuminemia, resulting in a larger extravascular space 
of distribution and diminished rate of delivery to the kidney 
(60, 61).
 2. In order to function, loop diuretics must exit the vascular 
capillary, traverse the interstitium, enter the tubular epithelial 
cell and be secreted into the tubular lumen where they block 
Na+, chloride, and other transporters. Typically in NS, there is 
expansion of the renal parenchymal interstitial fluid compart-
ment which reduces peritubular diuretic uptake.
 3. Some of the diuretic that enters the tubular lumen is bound to 
filtered albumin and rendered inactive (63, 64). In experimen-
tal in vivo microperfusion of the loop of Henle, the addition 
of albumin to the perfusate in a concentration similar to that 
seen in the tubular lumen in NS diminishes the response to 
intraluminal furosemide by about 50% (63). However, it is 
uncertain if this mechanism is important in humans. In one 
study of seven patients with NS, blocking of albumin binding 
to furosemide by the administration of sulfisoxazole had no 
effect on the diuretic response (65).
In clinical practice, this diuretic resistant state can be partly over-
come by administering a higher diuretic dosage in subjects with 
nephrotic edema compared with other edematous disorders (19). 
In younger children, furosemide is most often used to manage 
nephrotic edema. It is infused at 0.5 mg/kg/dose every 8–12 h, 
given at the start or at 1 h after administration of SPA. Also, a 
modest increase in urine Na+ excretion and volume has been 
reported in adults with marked hypoalbuminemia by infusing a 
solution consisting of furosemide added to SPA. In theory, this 
approach aids trapping of the diuretic within the vascular com-
partment, thereby increasing the rate of loop diuretic secretion 
into the tubular lumen (66).
A recent review of loop diuretics in managing nephrotic and 
other forms of systemic edema indicates several advantages of 
bumetanide, including greater bioavailability than furosemide 
as well as the convenience of 1:1 intravenous to oral conversion 
(67). However, because of high potency at low dosages this agent 
is somewhat difficult to titrate in smaller sized children. Because 
of a short half-life, all loop diuretics require multiple dosing. 
Ethacrynic acid is reserved for children with sulfa allergy. While 
popular in adults, there is limited experience with torsemide use 
in children.
In children who do not respond adequately to loop diuret-
ics, it is advisable to add a thiazide type diuretic in order to 
achieve diuretic synergy by way of sequential nephron blockade. 
Chlorothiazide can be given orally or intravenously and is 
particularly useful in small sized children or if gastrointestinal 
absorption is compromised. For oral use in children over 5 years 
old, the author prefers short-term use of metolazone (Zaroxolyn), 
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a long acting thiazide-like diuretic, which is secreted in the 
proximal tubule and has a plasma half-life of 36-hours; it is given 
at a dosage of 2.5–5.0 mg once daily. Like most loop diuretics, 
metolazone is also highly protein bound and, therefore, it is not 
dependent on normal GFR for it to be effective. When this is 
combined with bumetanide and SPA, a brisk diuresis is usually 
achieved.
Although ENac channel activation has been implicated in Na+ 
retention in NS of diverse etiologies, the efficacy of blocking this 
channel by amiloride is believed to be low because of the relatively 
small amount of Na+ arriving at the DCT. However, amiloride 
and other potassium sparing diuretics, such as spironolactone 
(1.25  mg/kg/dose), may be utilized in conjunction with loop 
diuretics.
New DiReCTiONS iN THe MANAGeMeNT 
OF NePHROTiC eDeMA
Aquaretics
Aquaretics are a newer group or class of diuretics which unlike 
conventional diuretics produce solute-free diuresis, or aqua-
resis. As discussed above, studies in untreated children with 
NS and underfill physiology have shown increased plasma 
and urinary concentrations of vasopressin or ADH (19). This 
together with presence of hyponatremia that is frequently 
found in these children is highly suggestive of water retention 
in excess of Na+ retention. These observations also apply to 
adults with NS (68–70) and provide the rationale for aquaretic 
use to manage nephrotic edema. A case report and early clinical 
trials (71) suggest an efficacy of brief courses of vasopressin 
2 receptor anatagonists, such as tolvaptan, or of somatostatin 
(Octeotide), in inducing aquaresis by inhibiting their common 
intracellular mediator, cAMP, thereby decreasing aquaporin 
channel insertion in the renal CD epithelium and abrogating 
anti-diuresis.
Urea channel inhibitors provide another newer approach 
to aquaresis (72–75). Use of these agents relies on the fact that 
humans and other mammals consuming a high protein diet gen-
erate nitrogen which is then excreted by the kidneys in the form of 
urea. The large amount of urea filtered at the glomerulus tends to 
promote an osmotic diuresis. To attenuate such diuresis the kid-
ney has “UT-A” (coded by the SLC14A2 gene) and “UT-B” (coded 
by the SLC14A1 gene) channels, which aid the accumulation of 
urea in the renal medullary interstitium. This action osmotically 
balances the urea in the CD lumen, thereby preventing urea-
dependent osmotic diuresis that would otherwise occur. Li et al. 
have identified a compound that inhibits the UT-B urea channel 
(76). Compounds that inhibit the UT-A channels could be poten-
tially more useful as aquaretic agents by blocking both the source 
of urea in the inner medulla (UT-A1 and UT-A3 channels in the 
inner medullary CD) and the countercurrent exchanger in the 
vascular bundles (UT-A2). Also, UT-A inhibitors are predicted to 
have fewer adverse effects, since UT-A’s only known physiological 
function is in the kidney, whereas UT-B inhibitors could cause 
hemolysis and other systemic adverse effects.
Like vaptans and somatostatin, urea channel inhibitors are of 
potential benefit in the treatment of hyponatremic disorders but 
may also be of benefit in managing edema associated with NS, 
particularly if excessive water retention is suspected on clinical 
evaluation. As with diuretics, aquaretics should only be consid-
ered in children with sufficient effective circulatory volume.
Other Potential Therapies of Nephrotic 
edema
Identification of molecules that initiate proteinuria or directly 
contribute to edema formation offers the possibility of modula-
tion of a greater number of potential targets so as to neutralize 
their detrimental effects. Currently, this area of research is in its 
infancy.
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